Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Oramed Pharmaceuticals Inc. (ORMP)

    4.1100 -0.1200 (-2.84%)
    At close: October 30 at 4:00:00 PM EDT
    4.1300 +0.0200 (+0.49%)
    After hours: October 30 at 4:00:11 PM EDT
    Trade ORMP on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for ORMP
    • Previous Close 4.2300
    • Open 4.2200
    • Bid 3.0300 x 200
    • Ask 5.2600 x 200
    • Day's Range 4.0800 - 4.2900
    • 52 Week Range 2.0900 - 5.4700
    • Volume 91,505
    • Avg. Volume 181,473
    • Market Cap (intraday) 170.965M
    • Beta (5Y Monthly) 1.28
    • PE Ratio (TTM) 1.00
    • EPS (TTM) 4.1300
    • Earnings Date (est.) Nov 12, 2026
    • Forward Dividend & Yield 0.25 (6.08%)
    • Ex-Dividend Date Jan 16, 2026
    • 1y Target Est 7.00

    Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

    oramed.com

    --

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Oramed Pharmaceuticals Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    ORMP
    54.69%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    ORMP
    83.70%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    ORMP
    134.50%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    ORMP
    81.17%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share (GAAP)

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings 78.16M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    0
    20M
    40M
    60M
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    7.00
    7.00 Average
    4.1100 Current
    7.00 High

    Latest Rating

    Date 9/9/2024
    Analyst HC Wainwright & Co.
    Rating Action Reiterates
    Rating Neutral
    Price Action --
    Price Target --
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -3.42%

    • Return on Equity (ttm)

      74.24%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      174.06M

    • Diluted EPS (ttm)

      4.1300

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      50.61M

    • Total Debt/Equity (mrq)

      0.23%

    • Levered Free Cash Flow (ttm)

      2.51M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    RDHL RedHill Biopharma Ltd.
    0.3878 -6.91%
    MNOV MediciNova, Inc.
    1.4000 0.00%
    BLRX BioLineRx Ltd.
    1.9900 -1.49%
    EOCN Eocene Ltd.
    3.1000 -3.73%
    CANF Can-Fite BioPharma Ltd.
    1.6200 -2.41%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: